The FDA Matters blog serves a broad readership of people "involved in FDA matters and for whom FDA matters."

Readers turn to the FDA Matters blog for insight, information and a fresh perspective about the agency and its interactions with Congress, media and stakeholders. In serving our readers, FDA Matters is not interested in ideology...only in how FDA can best serve the American people and the global community. Since there are many views on this: dialogue is encouraged and dissent is fine. Strong feelings are welcome, as long as they are politely expressed.

FDA Matters: The Grossman FDA Blog Report

FDA Matters
The Grossman FDA Report
  • Sequestration Has Less Impact on FDA? Just Not True
    “The Hill” newspaper recently reported that: “a survey of federal budgets devoted to developing and enforcing regulations found that many agencies will spend more in 2013 and 2014 than in previous years, indicating that the writing and enforcing of new regulations is largely unimpeded by the massive cuts, known as sequestration.” That certainly sounds authoritative…until you look at the analysis. In fact, the report’s authors appear to know nothing about the federal budget and have used inherently unreliable data in calculating FY 13 and FY 14 spending levels. One can only hope that the authors—allegedly academic experts--know more about regulatory policy than they do about federal budgets.
  • More Columns Coming; The Alliance for a Stronger FDA
    FDA Matters appreciates your patience. New columns will be coming in June, with fresh insights into FDA and the FDA-regulated world.  Meantime, I write a weekly column in the Friday Update, published by the Alliance for a Stronger FDA. If you want to receive the Friday Update when it's published each week, you can sign […]
  • FDA’s Indifferent Attitude Towards the First Amendment
    The FDA doesn’t care about the First Amendment rights of the companies it regulates. It cares even less about the “free speech” rights of those companies’ sales and marketing representatives. And why should the agency care? One of FDA’s primary missions is to protect the public health and safety of the American people from illegal, adulterated and misbranded products. Doing so involves restraining food, drug, device and cosmetics companies from committing fraudulent and deceptive acts that are not protected by companies’ commercial free speech rights. Nonetheless, FDA Matters envisions opportunities for FDA and industry to broaden permissible product communications. The key is understanding history, not constitutional law.